This is a different variant of M-Pox and I bet the trial was over the SIGA effect on the new variant. A) I should of thought of that and B) Bavarian may share the same problems and or properties that resulted in SIGa's failure..
If GeoVax can claim they can adjust faster and counter the new strain they could claim huge share.
Today will be interesting to watch. If Bavarian can hit the tape saying their drug is viable against the new strain it will explode up because they have the units made and the production facilities to meet demand. I doubt very seriously Geovax does...
So I'll be watching Bavarian for a mid day play.>